<VariationArchive VariationID="1979899" VariationName="NM_052845.4(MMAB):c.649dup (p.Ser217fs)" VariationType="Duplication" Accession="VCV001979899" Version="2" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-02-29" DateCreated="2023-02-08" MostRecentSubmission="2024-02-28">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="2045576" VariationID="1979899">
      <GeneList>
        <Gene Symbol="MMAB" FullName="metabolism of cobalamin associated B" GeneID="326625" HGNC_ID="HGNC:19331" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>12q24.11</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="12" Accession="NC_000012.12" start="109553715" stop="109573504" display_start="109553715" display_stop="109573504" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="12" Accession="NC_000012.11" start="109991519" stop="110011357" display_start="109991519" display_stop="110011357" Strand="-" />
          </Location>
          <OMIM>607568</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_052845.4(MMAB):c.649dup (p.Ser217fs)</Name>
      <CanonicalSPDI>NC_000012.12:109557131:T:TT</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>12q24.11</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="12" Accession="NC_000012.12" start="109557131" stop="109557132" display_start="109557131" display_stop="109557132" variantLength="1" positionVCF="109557131" referenceAlleleVCF="C" alternateAlleleVCF="CT" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="12" Accession="NC_000012.11" start="109994936" stop="109994937" display_start="109994936" display_stop="109994937" variantLength="1" positionVCF="109994936" referenceAlleleVCF="C" alternateAlleleVCF="CT" />
      </Location>
      <ProteinChange>S217fs</ProteinChange>
      <HGVSlist>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_007096.1" sequenceAccession="NG_007096" sequenceVersion="1" change="g.21366dup">
            <Expression>NG_007096.1:g.21366dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="non-coding">
          <NucleotideExpression sequenceAccessionVersion="NR_038118.2" sequenceAccession="NR_038118" sequenceVersion="2" change="n.760dup">
            <Expression>NR_038118.2:n.760dup</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001619" Type="non-coding transcript variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_052845.4" sequenceAccession="NM_052845" sequenceVersion="4" change="c.649dup" MANESelect="true">
            <Expression>NM_052845.4:c.649dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_443077.1" sequenceAccession="NP_443077" sequenceVersion="1" change="p.Ser217fs">
            <Expression>NP_443077.1:p.Ser217fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000012.11" sequenceAccession="NC_000012" sequenceVersion="11" change="g.109994937dup" Assembly="GRCh37">
            <Expression>NC_000012.11:g.109994937dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000012.12" sequenceAccession="NC_000012" sequenceVersion="12" change="g.109557132dup" Assembly="GRCh38">
            <Expression>NC_000012.12:g.109557132dup</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_052845.4(MMAB):c.649dup (p.Ser217fs) AND Methylmalonic aciduria, cblB type" Accession="RCV002756216" Version="2">
        <ClassifiedConditionList TraitSetID="791">
          <ClassifiedCondition DB="MedGen" ID="C1855102">Methylmalonic aciduria, cblB type</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2022-05-15" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2022-05-15" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2023-02-08" MostRecentSubmission="2024-02-28">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">16410054</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">21604717</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="791" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="2915" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Methylmalonic aciduria, cblB type</ElementValue>
                <XRef ID="MONDO:0009614" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Vitamin B12-responsive methylmalonic acidemia type cblB</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">METHYLMALONIC ACIDURIA, VITAMIN B12-RESPONSIVE, DUE TO DEFECT IN SYNTHESIS OF ADENOSYLCOBALAMIN, cblB TYPE</ElementValue>
                <XRef Type="MIM" ID="251110" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Methylmalonic acidemia cblB type</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">For this GeneReview, the term "isolated methylmalonic acidemia" refers to a group of inborn errors of metabolism associated with elevated methylmalonic acid (MMA) concentration in the blood and urine that result from the failure to isomerize (convert) methylmalonyl-coenzyme A (CoA) into succinyl-CoA during propionyl-CoA metabolism in the mitochondrial matrix, without hyperhomocysteinemia or homocystinuria, hypomethioninemia, or variations in other metabolites, such as malonic acid. Isolated MMA is caused by complete or partial deficiency of the enzyme methylmalonyl-CoA mutase (mut0 enzymatic subtype or mut– enzymatic subtype, respectively), a defect in the transport or synthesis of its cofactor, 5-deoxy-adenosyl-cobalamin (cblA, cblB, or cblD-MMA), or deficiency of the enzyme methylmalonyl-CoA epimerase. Prior to the advent of newborn screening, common phenotypes included: Infantile/non-B12-responsive form (mut0 enzymatic subtype, cblB), the most common phenotype, associated with infantile-onset lethargy, tachypnea, hypothermia, vomiting, and dehydration on initiation of protein-containing feeds. Without appropriate treatment, the infantile/non-B12-responsive phenotype could rapidly progress to coma due to hyperammonemic encephalopathy. Partially deficient or B12-responsive phenotypes (mut– enzymatic subtype, cblA, cblB [rare], cblD-MMA), in which symptoms occur in the first few months or years of life and are characterized by feeding problems, failure to thrive, hypotonia, and developmental delay marked by episodes of metabolic decompensation. Methylmalonyl-CoA epimerase deficiency, in which findings range from complete absence of symptoms to severe metabolic acidosis. Affected individuals can also develop ataxia, dysarthria, hypotonia, mild spastic paraparesis, and seizures. In those individuals diagnosed by newborn screening and treated from an early age, there appears to be decreased early mortality, less severe symptoms at diagnosis, favorable short-term neurodevelopmental outcome, and lower incidence of movement disorders and irreversible cerebral damage. However, secondary complications may still occur and can include intellectual disability, tubulointerstitial nephritis with progressive impairment of renal function, "metabolic stroke" (bilateral lacunar infarction of the basal ganglia during acute metabolic decompensation), pancreatitis, growth failure, functional immune impairment, bone marrow failure, optic nerve atrophy, arrhythmias and/or cardiomyopathy (dilated or hypertrophic), liver steatosis/fibrosis/cancer, and renal cancer.</Attribute>
                <XRef ID="NBK1231" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="9479" />
                <XRef ID="9479" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301409</ID>
                <ID Source="BookShelf">NBK1231</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Elevated%20C3%20Acylcarnitine%20PA%20and%20MA.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Elevated C3 Acylcarnitine, Propionic Acidemia (PA) and Methylmalonic Acidemia (MMA), 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/C3-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Propionic and Methylmalonic Acidemia: C3 Elevated, 2022</CitationText>
              </Citation>
              <XRef ID="28" DB="Orphanet" />
              <XRef ID="79311" DB="Orphanet" />
              <XRef ID="C1855102" DB="MedGen" />
              <XRef ID="MONDO:0009614" DB="MONDO" />
              <XRef Type="MIM" ID="251110" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="5714827" SubmissionDate="2024-02-07" DateLastUpdated="2024-02-28" DateCreated="2023-02-07">
        <ClinVarSubmissionID localKey="10911800|MedGen:C1855102" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV003026656" DateUpdated="2024-02-28" DateCreated="2023-02-07" Type="SCV" Version="2" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-05-15">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">16410054</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">21604717</ID>
          </Citation>
          <Comment>This sequence change creates a premature translational stop signal (p.Ser217Lysfs*2) in the MMAB gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 34 amino acid(s) of the MMAB protein. This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with MMAB-related conditions. This variant disrupts a region of the MMAB protein in which other variant(s) (p.Gln234*) have been determined to be pathogenic (PMID: 16410054, 21604717). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="MMAB" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000012.11:g.109994936_109994937insT</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C1855102" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12506961</SubmissionName>
          <SubmissionName>SUB14200269</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="5714827" TraitType="Disease" MappingType="XRef" MappingValue="C1855102" MappingRef="MedGen">
        <MedGen CUI="C1855102" Name="Methylmalonic aciduria, cblB type" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

